Dr. Reddys Laboratories (RDY)
(Delayed Data from NYSE)
$81.43 USD
-1.89 (-2.27%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $81.45 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$81.43 USD
-1.89 (-2.27%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $81.45 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Zacks News
Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q2
by Zacks Equity Research
Dr. Reddy's (RDY) surpasses earnings and revenue estimates on strength across segments in the second quarter of fiscal 2019.
IMF Predicts Strong GDP Growth for India: Stocks in Focus
by Zacks Equity Research
Strong growth in the Indian economy should aid stocks from this region.
Dr. Reddy's Sells Antibiotic Production Hub to UAE Drugmaker
by Zacks Equity Research
Dr. Reddy's (RDY) divests its Bristol, TN-based antibiotic manufacturing site and related assets to an Abu Dhabi-based company.
Dr. Reddy's (RDY) Presence in Generics Market Remains Strong
by Zacks Equity Research
Dr. Reddy's has a strong hold in the generics market. New product launches, especially complex generics, are likely to drive the generics business at regular intervals.
Indian Stocks in Focus as IMF Appreciates Its Economic Growth
by Nalak Das
According to the IMF, Indian economy is gaining momentum as a result of several policy reforms taken by Prime Minister Narendra Modi's administration.
Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q1
by Zacks Equity Research
Dr Reddy's (RDY) surpasses both earnings and sales year over year in the first quarter of fiscal 2019.
Is First Trust BICK Index Fund (BICK) a Hot ETF Right Now?
by Sweta Killa
Smart Beta ETF report for BICK
Lilly Wins Favorable Ruling From U.S. Court in Alimta Row
by Zacks Equity Research
Lilly (LLY) gets a favorable ruling from a U.S. district court in a patent related dispute against Dr. Reddy's Laboratories, concerning its key cancer drug Alimta's vitamin regimen patent.
Company News For Jun 18, 2018
by Zacks Equity Research
Companies In The News are: GOOS,FB,RDY,FOXA
Dr. Reddy's/Mylan Get FDA Nod for First Generic of Suboxone
by Zacks Equity Research
Dr. Reddy's (RDY) and Mylan announced that the FDA approved the first generic version of Suboxone (Buprenorphine and Naloxone Sublingual Film) under-the-tongue film for the treatment of opioid addiction.
BioMarin Begins Pediatric Study on Achondroplasia Candidate
by Zacks Equity Research
BioMarin Pharmaceutical (BMRN) initiates phase II study on vosoritide for the treatment of achondroplasia in infants and children up to five years of age.
Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals
by Zacks Equity Research
Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals
Pharma Stocks Weighed Down by Competition, Generic Pressure
by Zacks Equity Research
Although pharma and biotech sectors rebounded in 2017 and started 2018 on an optimistic note, drug companies may find it a bit difficult to justify their high prices.
J&J (JNJ) Gets FDA Nod for New Prostate Cancer Treatment (Revised)
by Zacks Equity Research
J&J (JNJ) Gets FDA approval for Erleada (apalutamide) for the treatment of non-metastatic castration-resistant prostate cancer.
J&J (JNJ) Gets FDA Nod for New Prostrate Cancer Treatment
by Zacks Equity Research
J&J (JNJ) Gets FDA approval for Erleada (apalutamide) for the treatment of non-metastatic castration-resistant prostate cancer.
Generic Drugmakers to Dump as Teva's Woes Continue in 2018
by Zacks Equity Research
The generic industry is facing several challenges pulling down several companies including Teva (TEVA).
VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down
by Zacks Equity Research
VIVUS (VVUS) reported third-quarter results wherein it reported narrower-than- expected loss. However, Qsymia sales fell from the year-ago period.
Teva Reintroduces Generic Depo-Provera Injection in U.S.
by Zacks Equity Research
Teva (TEVA) announced the reintroduction of the generic equivalent to Depo-Prover Contraceptive Injection 150 mg/mL in the United States.
Dr. Reddy's Laboratories (RDY) Surges: Stock Moves 5.7% Higher
by Zacks Equity Research
Dr. Reddy's Laboratories (RDY) was a big mover last session, as the company saw its shares rise nearly 6% on the day amid huge volumes.
Teva's New CEO Brings No Relief: Generic Drugmakers to Dump
by Zacks Equity Research
The New CEO appointment at Teva (TEVA has once again shifted focus to the Generic Drug industry, which is presently facing several challenges.
VIVUS Settles with Teva on Weight Management Drug Generic
by Zacks Equity Research
VIVUS, Inc. (VVUS) announced that it has entered into a settlement agreement with Teva Pharmaceutical Industries Limited (TEVA), thereby resolving a three-year old patent litigation related to its weight management drug Qsymia.
Pricing, Competition Remain Headwinds for Pharma in 2017
by Arpita Dutt
Fears regarding the drug pricing issue have waned, it will nevertheless remain a headwind in the near term.
New Strong Sell Stocks for April 20th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Mylan Down on FDA Warning Letter to Manufacturing Facility
by Zacks Equity Research
Shares of Mylan, Inc. (MYL) dropped 2% after the company received a warning letter from the FDA for its manufacturing facility in India
New Strong Sell Stocks for April 5th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: